James M. Frates
Chief Financial OfficerMr. James M. Frates, also known as Jim, M.B.A., has been the Chief Financial Officer at Amylyx Pharmaceuticals, Inc. since January 25, 2021 and served as its Director since January 25, 2021. He is Director of Tortugas Neuroscience, Inc. from September 2026. He serves as Member of Advisory Board at Eagle Genomics Ltd. since May 2021. He has been the Chief Financial Officer, Vice President, Treasurer and Assistant Secretary of Alkermes Development Corporation II, General Partner of Alkermes Clinical Partners LP since June 1998. He served as Chief Financial Officer at Alkermes Plc since September 2011 until January 2021 and served as its Senior Vice President since June 1998 until January 2021. He served as Treasurer and Chief Financial Officer of Alkermes Plc since September 16, 2011 to March 2019. He managed all aspects of finance and helped oversee the 2011 business combination with Elan Drug Technologies (EDT). Mr. Frates served as Vice President and Treasurer of Alkermes, Inc., a subsidiary of Alkermes Plc since June 1998 until May 2007, its Chief Financial Officer since June 1998 until September 16, 2011 and its Senior Vice President since May 2007 until September 16, 2011. He served as the Principal Accounting Officer of Alkermes Development Corporation II, a General Partner of Alkermes Clinical Partners LP. He served as the Chief Financial Officer, Assistant Secretary, Treasurer and Vice President of Alkermes Development Corporation II, a General Partner of Alkermes Clinical Partners LP since June 1998. Mr. Frates joined Alkermes in 1998. He began his financial career in health care investment banking at Morgan Stanley & Company. From June 1996 to July 1998, he was employed at Robertson, Stephens & Company, served as Vice President in Investment Banking and Vice President in charge of the East Coast Life Sciences Practice. He served at Morgan Stanley & Co. He served as Vice Chairman of Supervisory Board at Agennix AG. He served as Vice Chairman of Supervisory Board at GPC Biotech AG and as its a Member of Supervisory Board since September 2004. He has been a Director of Alkermes Development Corporation II since June 1998. Mr. Frates joined the Sage Therapeutics, Inc. in May 2014. He served as a Director of Alkermes Plc. He served as a Director of Alkermes Development Corporation II, a general partner of Alkermes Clinical Partners LP since June 1998. He served as Member of Supervisory Board at Agennix AG since September 2004. Mr. Frates received a A.B. in Political Science and Government from Harvard College and an M.B.A. from Harvard Graduate School of Business Administration in June 1996. He was Independent Director of Sage Therapeutics, Inc. from May 2014 to July 31, 2025.
Positions
- Company NameAmylyx Pharmaceuticals, Inc.Stock CodeAMLXPositionChief Financial OfficerColleagues
- JBJoshua B. CohenCo-Founder, Co-CEO & Director
- GMGeorge Mclean MilneIndependent Chairman of the Board
- JBJustin B. KleeCo-CEO & Director
- CLCamille L. BedrosianChief Medical Officer
- THTom HolmesChief Technical Operations Officer
- RERudolph Emile TanziChairman of The Scientific Advisory Board
- PRPaul R. FonteyneIndependent Director
